Matinas BioPharma Holdings, Inc. – AMEX:MTNB

Add to watchlist

$1.728

+1.21

+233.63%

Market closed

Open in 2 days

+205.06%

month

+205.06%

quarter

+113.17%

year

Market Cap	2.64M
Enterprise value	94.90M

P/E	-4.5
EV/Sales	44.66
EV/EBITDA	-2.92
Price/Sales	45.93
Price/Book	2.66
PEG ratio	-0.38
EPS	-0.10

Revenue	N/A
EBITDA	-23.36M
Income	-23.25M
Revenue Q/Q	-100%
Revenue Y/Y	-125.58%

Profit margin	-1548.13%
Oper. margin	-1799.42%
Gross margin	0%
EBIT margin	-1799.42%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Profit margin
Jun 2023	0	-6.06M
Sep 2023	0	-6.05M
Dec 2023	-1.09M	-5.31M	484.85%
Mar 2024	0	-5.82M

Matinas BioPharma Holdings Financials Estimate

Q Y

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Analyst Estimates
2025	63.91M	-34.61M	-54.16%
2026	93.32M	-35.83M	-38.39%
2027	45.20M	-9.77M	-21.63%
2028	120.08M	52.14M	43.42%

Analysts Price target
Financials & Ratios estimates

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Payout ratio
Payout ratio	0%

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Dividend Yield
2019	677.94%
2020	254.99%
2021	397.4%
2022
2023

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Debt to assets
Jun 2023	34025000	6.17M	18.14%
Sep 2023	29791000	6.64M	22.29%
Dec 2023	65578000	46.33M	70.65%
Mar 2024	19610000	5.05M	25.76%

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Cash Flow
Jun 2023	-2.19M	6.19M	-1K
Sep 2023	-4.41M	1.08M	-1K
Dec 2023	-4.57M	2.96M	-1K
Mar 2024	-5.76M	2M	53K

Matinas BioPharma Holdings alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Matinas BioPharma Holdings
Employees

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Employee count
Aug 2023	34
Sep 2023	34
Oct 2023	34
Nov 2023	34
Dec 2023	34
Jan 2024	34
Feb 2024	34
Mar 2024	34
Apr 2024	34
May 2024	32
Jun 2024	32
Jul 2024	32

Matinas BioPharma Holdings
Hedge Funds Holdings Q1 2023

6.53% -6.46%

of MTNB is owned by hedge funds

37 -19

hedge funds hold MTNB stock

13.72M -13.58M

shares is hold by hedge funds

MTNB hedge funds holdings changes

Matinas BioPharma Holdings
Insider Trading

Matinas BioPharma Holdings, Inc. (AMEX:MTNB): Insider trades (number of shares)
Period	Buy	Sel
Nov 2019	194500	0
Mar 2020	20000	0
May 2020	100000	0
Aug 2020	20000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	21 Aug 2020	STERN ADAM K director director	Common Stock, par value $0.0001 per share	20,000	$0.83	$16,600
Purchase	14 May 2020	LEPORE PATRICK G director director	Common Stock, par value $0.0001 per share	100,000	N/A	N/A
Option	3 Apr 2020	STERN ADAM K director director	Common Stock, par value $0.0001 per share	278,407	N/A	N/A
Option	3 Apr 2020	STERN ADAM K director director	Warrant (right to buy)	952,676	N/A	N/A
Purchase	17 Mar 2020	STERN ADAM K director director	Common Stock, par value $0.0001 per share	10,000	$0.65	$6,500
Purchase	17 Mar 2020	JABBOUR JEROME D director, officer..	Common Stock, par value $0.0001 per share	10,000	N/A	N/A
Purchase	25 Nov 2019	KUCINSKI KEITH A officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock, par value $0.0001 per share	58,000	$1.23	$71,166
Purchase	22 Nov 2019	KUCINSKI KEITH A officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock, par value $0.0001 per share	36,500	N/A	N/A
Purchase	15 Nov 2019	LEPORE PATRICK G director director	Common Stock, par value $0.0001 per share	100,000	N/A	N/A
Purchase	20 Aug 2019	ENDE ERIC J director director	Common Stock, par value $0.0001 per share	20,000	N/A	N/A

MTNB insider trading transactions

Matinas BioPharma Holdings
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 8 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 9 Aug 2023	Q2 2023 Earnings Call Transcript

MTNB earnings call transcripts

Matinas BioPharma Holdings
Executives

Insider	Age	Compensation
Mr. Jerome D. Jabbour J.D. (1974) Co-Founder, Chief Executive Officer, Pres & Director	51	$750,000
Dr. James J. Ferguson FACC, M.D. (1954) Chief Medical Officer	71	$560,000
Dr. Theresa Matkovits Ph.D. (1967) Chief Devel. Officer	58	$490,000

Matinas BioPharma Holdings
Latest News

Thursday, 31 October 2024
06:30	Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction	globenewswire.com
Wednesday, 14 August 2024
21:40	Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript	seekingalpha.com
16:05	Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update	globenewswire.com
Wednesday, 7 August 2024
07:00	Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024	globenewswire.com
Monday, 24 June 2024
08:30	Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program	globenewswire.com
Thursday, 13 June 2024
07:00	Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.	globenewswire.com
Thursday, 16 May 2024
14:27	Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch	investorplace.com
07:00	New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024	globenewswire.com
Thursday, 9 May 2024
21:56	MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024	InvestorPlace
19:47	Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript	Seeking Alpha
Thursday, 28 March 2024
23:20	Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 8 November 2023
22:44	Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 7 November 2023
09:26	Penny Stocks To Buy Now? 3 to Watch With Big News	PennyStocks
Thursday, 12 October 2023
11:26	Top trending biotech stocks: ANVS, MTNB, AVTX, TPST	Invezz
Thursday, 28 September 2023
07:00	Matinas BioPharma to Present at Two Investment Conferences in October 2023	GlobeNewsWire
Wednesday, 6 September 2023
07:00	Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference	GlobeNewsWire
Wednesday, 26 July 2023
08:00	Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023	GlobeNewsWire
Thursday, 11 May 2023
07:30	Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023	GlobeNewsWire
Wednesday, 10 May 2023
18:59	Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 3 May 2023
07:00	Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023	GlobeNewsWire
Thursday, 27 April 2023
18:36	7 Small-Cap Biotech Stocks with Massive Potential	InvestorPlace
Wednesday, 15 March 2023
20:26	Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript	Seeking Alpha
Wednesday, 8 March 2023
07:00	Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023	GlobeNewsWire
Wednesday, 2 November 2022
20:43	Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call Transcript	Seeking Alpha
19:35	Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research
Friday, 21 October 2022
13:27	10 Top Penny Stocks To Buy For Uner $1 Right Now	PennyStocks
07:00	Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference	GlobeNewsWire
Wednesday, 12 October 2022
07:00	Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022	GlobeNewsWire
Tuesday, 30 August 2022
11:18	After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)	Zacks Investment Research
Thursday, 11 August 2022
13:53	Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha

Frequently Asked Questions (FAQ)

What's the price of Matinas BioPharma Holdings stock today?

One share of Matinas BioPharma Holdings stock can currently be purchased for approximately $1.73.
When is Matinas BioPharma Holdings's next earnings date?

Unfortunately, Matinas BioPharma Holdings's (MTNB) next earnings date is currently unknown.
Does Matinas BioPharma Holdings pay dividends?

No, Matinas BioPharma Holdings does not pay dividends.
How much money does Matinas BioPharma Holdings make?

Matinas BioPharma Holdings has a market capitalization of 2.64M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 65.62% to 1.1M US dollars.
What is Matinas BioPharma Holdings's stock symbol?

Matinas BioPharma Holdings, Inc. is traded on the AMEX under the ticker symbol "MTNB".
What is Matinas BioPharma Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Matinas BioPharma Holdings?

Shares of Matinas BioPharma Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Matinas BioPharma Holdings's key executives?
Matinas BioPharma Holdings's management team includes the following people:
- Mr. Jerome D. Jabbour J.D. Co-Founder, Chief Executive Officer, Pres & Director(age: 51, pay: $750,000)
- Dr. James J. Ferguson FACC, M.D. Chief Medical Officer(age: 71, pay: $560,000)
- Dr. Theresa Matkovits Ph.D. Chief Devel. Officer(age: 58, pay: $490,000)
Is Matinas BioPharma Holdings founder-led company?

Yes, Matinas BioPharma Holdings is a company led by its founder Mr. Jerome D. Jabbour J.D..
How many employees does Matinas BioPharma Holdings have?

As Jul 2024, Matinas BioPharma Holdings employs 32 workers, which is 6% less then previous quarter.
When Matinas BioPharma Holdings went public?

Matinas BioPharma Holdings, Inc. is publicly traded company for more then 11 years since IPO on 21 Jul 2014.
What is Matinas BioPharma Holdings's official website?

The official website for Matinas BioPharma Holdings is matinasbiopharma.com.
Where are Matinas BioPharma Holdings's headquarters?

Matinas BioPharma Holdings is headquartered at 1545 Route 206 South, Bedminster, NJ.
How can i contact Matinas BioPharma Holdings?

Matinas BioPharma Holdings's mailing address is 1545 Route 206 South, Bedminster, NJ and company can be reached via phone at +90 84848805.

Matinas BioPharma Holdings, Inc.

matinasbiopharma.com

Exchange:

AMEX

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

+90 84848805

1545 Route 206 South
Bedminster, NJ 07921

CIK: 0001582554
ISIN: US5768101058
CUSIP: 576810105